Navigation Links
Helix BioPharma Provides Updates on Topical Interferon Alpha-2b and L-DOS47 Following Pre-IND Meetings With the U.S. FDA
Date:10/6/2009

n Germany. The pharmacokinetic trial will enroll up to 28 patients in order to obtain a minimum of 12 patients for evaluation for the primary study endpoint. Helix plans to proceed with filing its Phase II/III IND if sufficient positive data are obtained from the first 12 patients completing the study, and all other study findings are positive. If required, Helix may expand the data set beyond the first 12 patients if the results indicate more data are needed. Preliminary findings from patients enrolled so far in this study show no significant systemic interferon alpha-2b exposure. While the study is progressing, enrollment to date has been slower than previously anticipated. Given the recruiting challenges to date, the Company has revised its timeline for the pharmacokinetic study. In order to enhance the patient recruitment rate, the Company intends to open additional clinical sites during the Company's second quarter of fiscal 2010. Assuming the patient recruitment rate improves as planned, Helix now expects it will take until the end of its third quarter of fiscal 2010 for the 12 minimum required patients to complete the study, and up to the end of its first quarter of fiscal 2011 for all 28 patients to do so.

Helix has also confirmed that it must successfully complete its ongoing, scale-up, GMP engineering batch manufacturing and preliminary stability testing program before filing its U.S. Phase II/III IND.

Given the anticipated timeline for the pharmacokinetic study activities, and assuming successful completion of the scale-up GMP engineering batch manufacturing, Helix now projects that its U.S. Phase II/III IND filing will occur, at the earliest, in its fourth quarter of fiscal 2010. This revised timeline is subject to the successful and timely completion of these activities and assumes that no events occur which could cause further delay.

As part of the pre-IND meeting, Helix has also confirmed its previously
'/>"/>

SOURCE Helix BioPharma Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Helix Receives Approval to Open Sites in Germany for its Ongoing Clinical Trial With Topical Interferon Alpha-2b in Patients With Ano-Genital Warts
2. J. Craig Venter, Ph.D. Receives Double Helix Medal from Cold Spring Harbor Laboratory
3. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
4. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
5. Nabi Biopharmaceuticals Announces Continued Positive NicVAX Phase 2b Data at Nine Months
6. Keryx Biopharmaceuticals to Present at William Blair & Company Small-Cap Growth Stock Conference
7. Morria Biopharmaceuticals Plc Initiates Phase I Clinical Study of MRX-4 in Allergic Rhinitis
8. Keryx Biopharmaceuticals, Inc. Announces Positive Preliminary Phase 2 Data on KRX-0401 in Patients with Chemo-Insensitive Rare Sarcoma
9. Nabi Biopharmaceuticals Announces Successful Completion of NicVAX(R) Phase 2b Trial; Drug Shows Statistically Significant Rates of Smoking Cessation and Continuous Long-Term Smoking Abstinence at 12 Months
10. Inspiration Biopharmaceuticals Announces Filing of IND for Novel Recombinant Factor IX Product, IB1001, for the Treatment of Hemophilia B
11. Immunosyn Announces Biozyme Labs Receipt of MHRA Manufacturing License Approval in Europe for the Biopharmaceutical SF-1019
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 24, 2014  The International Trade Commission ... ResMed (RMD) against BMC Medical. In a notice issued on ... found that ResMed,s patent on its humidifier was invalid. ... a "monumental win". "We are very excited with the ITC,s ... position that we have taken since the very beginning on ...
(Date:12/24/2014)... LONDON , December 24, 2014 /PRNewswire/ ... expected to grow at an average rate of 8.1%. ... and volume. Hip, knee and spine surgeries are the ... emerging economies they have a lower penetration. Increased number ... use of composites. Non-metallic orthopedic devices have gained popularity ...
(Date:12/24/2014)... Dec. 23, 2014 ResMed (NYSE: RMD ... action against Chinese medical device manufacturer BMC Medical Co., Ltd. ... that BMC,s masks listed below infringe ResMed,s patents, and entered ... masks in the United States : ... mask , Willow nasal pillows mask , iVolve ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... Percutaneous Administration (CUPID) Data Highlight Safety Profile and ... 26 Celladon Corporation today announced that results ... advanced heart failure, including Phase 1/2 data of ... Zsebo, PhD, President and CEO, Celladon Corporation and ...
... 26 Senesco Technologies, Inc. ("Senesco" or the "Company") ... mouse influenza survival studies that were conducted in Dr. William Scheld,s ... Mice treated with an siRNA against Senesco,s Factor 5A gene ... rate for mice that received no treatment or a control siRNA.A ...
Cached Medicine Technology:Celladon Corporation Announces Presentation of First-in-Human Gene Transfer to Treat Heart Failure at the 12th Annual Meeting of the American Society of Gene Therapy 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 2Senesco Announces H1N1 Influenza Survival Test Results in Mice 3
(Date:12/25/2014)... The click strand woven bamboo flooring ... Today, the business announces a click strand woven ... 30, 2015. , Click strand woven bamboo flooring ... a well-known brand in the bamboo industry. It ... reliable bamboo flooring supplier. , “We are happy ...
(Date:12/25/2014)... (PRWEB) December 26, 2014 “Every three months ... market changes. A-line sweetheart evening dress will be one of ... sales manager of Yunx.co.uk says. Today, the company releases 26 ... discounts, up to 80% off. , “We are trying ... unique style with our latest designs. Along with affordable prices, ...
(Date:12/25/2014)... 2014 Recently, BellasDress has ... its wedding dresses. BellasDress has chosen their best-selling lace ... choices for the holiday season. , Now, BellasDress.com ... wedding gowns here at discount prices. The business hopes ... its website. , “All our elegant products ...
(Date:12/25/2014)... 2014 Recently, LunaDress.co.uk has updated its blog to ... accessories. Now, all of the models at LunaDress.co.uk come with big ... lifts the wedding veil can turn out to be a most ... wedding veil can always bring surprise to a wedding. On the ... to choose veils for a big day . , Going ...
(Date:12/25/2014)... Among early stage breast cancer patients who undergo chemotherapy ... will eventually develop leukemia as a result of their ... from a review of more than 20,000 breast cancer ... that the risk for developing treatment-related leukemia, though low, ... "The frequency of bone marrow cancers such as leukemia ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... last week could significantly increase the success rate of ... has indicated that rejection of animal cells and organs ... the presence of the gene alpha 1,3 galactosyl transferase. ... sugar// to the surface of pig cells, flagging them ...
... heart arteries flowing easily after angioplasty shows fantastic success ... the common procedure.Doctors released the longest follow up ... testing on 30 patients over three years, they found ... unheard of in medicine.// ,More than 1 million ...
... Using modern brain imaging techniques, scientists have indicated the ... are going to be stored or deleted. The study ... of Technology (MIT) and reported to the American Association ... ,The researchers coupled a number of different ...
... more precise predictions of a person's risk of a fatal ... journal suggested the test, which measures levels of the protein ... trouble than traditional cholesterol tests and may one day lead ... of the strongest risk factors for developing coronary artery disease ...
... will probably have to depend on current anthrax vaccines ... Second-generation vaccines are in the works but not ready. ... to go, approved by the FDA.// ,The government ... anthrax vaccine to resume shipping after four years in ...
... lines could aggregate genetic abnormalities over time and new ... Dr.Vogelstein, chairman of a key stem cell research committee ... the current stem cell lines are problematic because ... cell divide in a tissue culture it accumulates mutations. ...
Cached Medicine News:Health News:Xenotransplantation “breakthrough” 2Health News:A ray of hope in Angioplasty dilemma 2Health News:Blood Test May help Heart Prediction 2Health News:New Stem Cells lines will be required 2
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTN/1Q-CAB chairs are recommended for the ... room, static control, health care and ...
... Basic ergonomic chairs with concave ... support • Select options like seats, ... • BTN/1Q-CAB chairs are recommended for ... clean room, static control, health care ...
... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
Medicine Products: